Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Mena

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Journal of Neuroimmunology|January 1, 1990
Autoantigens in human neuroblastoma cellsJ Srinivasan, A P Hays, F P Thomas, et al.
Neurologia (Barcelona, Spain)|April 1, 1997
[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]J García de Yébenes, D Mateo, M A Pino, et al.
Parkinsonism & Related Disorders|January 1, 1996
Changes induced by ovariectomy on the acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat poor metabolizer of debrisoquineF J Jiménez-Jiménez, M A Mena, J García-Agúndez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1987
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's diseaseJ G de Yebenes, S Fahn, S Lovelle, et al.
Archivos De Neurobiologia|November 1, 1991
[Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease]G Sanchís, M A Mena, R Martín del Río, et al.
Human Molecular Genetics|May 16, 2006
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau proteinJ Menéndez, J A Rodríguez-Navarro, R M Solano, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1988
Neurochemical findings in neuroacanthocytosisJ G de Yebenes, M F Brin, M A Mena, et al.
Journal of Neurochemistry|July 1, 1991
Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquineF J Jiménez-Jiménez, C Tabernero, M A Mena, et al.
Parkinsonism & Related Disorders|July 2, 2008
Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeysJ G de Yébenes, R S Pernaute, J M Garrido, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 17, 2004
Levodopa in the treatment of Parkinson's disease: current controversiesC Warren Olanow, Yves Agid, Yoshi Mizuno, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Journal of Neuroimmunology|January 1, 1990
Autoantigens in human neuroblastoma cellsJ Srinivasan, A P Hays, F P Thomas, et al.
Neurologia (Barcelona, Spain)|April 1, 1997
[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]J García de Yébenes, D Mateo, M A Pino, et al.
Parkinsonism & Related Disorders|January 1, 1996
Changes induced by ovariectomy on the acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat poor metabolizer of debrisoquineF J Jiménez-Jiménez, M A Mena, J García-Agúndez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1987
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's diseaseJ G de Yebenes, S Fahn, S Lovelle, et al.
Archivos De Neurobiologia|November 1, 1991
[Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease]G Sanchís, M A Mena, R Martín del Río, et al.
Human Molecular Genetics|May 16, 2006
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau proteinJ Menéndez, J A Rodríguez-Navarro, R M Solano, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1988
Neurochemical findings in neuroacanthocytosisJ G de Yebenes, M F Brin, M A Mena, et al.
Journal of Neurochemistry|July 1, 1991
Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquineF J Jiménez-Jiménez, C Tabernero, M A Mena, et al.
Parkinsonism & Related Disorders|July 2, 2008
Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeysJ G de Yébenes, R S Pernaute, J M Garrido, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 17, 2004
Levodopa in the treatment of Parkinson's disease: current controversiesC Warren Olanow, Yves Agid, Yoshi Mizuno, et al.
Pageof 8